Raymond James & Associates Alkermes Plc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Alkermes Plc. stock. As of the latest transaction made, Raymond James & Associates holds 18,387 shares of ALKS stock, worth $448,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,387
Previous 17,917
2.62%
Holding current value
$448,091
Previous $497,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALKS
# of Institutions
356Shares Held
180MCall Options Held
522KPut Options Held
463K-
Black Rock Inc. New York, NY29.2MShares$711 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.2MShares$491 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.9MShares$363 Million0.07% of portfolio
-
State Street Corp Boston, MA9MShares$219 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.33MShares$203 Million0.03% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...